SCHEMBL5890971

SCHEMBL5890971

CN1CCN(c2cc(Cl)cc3c(-c4ccnc(NC5CCCC5)n4)c(-c4ccc(F)cc4)nn23)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.49
EGFR P00533 1/20 0.49
MAPK9 P45984 1/20 0.49
IKBKB O14920 1/20 0.48
CSNK1D P48730 1/20 0.47
HRH4 Q9H3N8 1/20 0.46
MAPK14 Q16539 2/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
KCNH2 Q12809 1/20 0.42
EIF2AK2 P19525 1/20 0.42
CDK4 P11802 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GSK3B P49841 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5890491 0.93 CSNK1D (0.49) MAPK8EGFRMAPK9IKBKBCSNK1D
SCHEMBL5890905 0.90 CSNK1D (0.57) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5890649 0.85 CSNK1D (0.51) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5891079 0.85 CSNK1D (0.50) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5890640 0.84 CSNK1D (0.49) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5890913 0.83 CSNK1D (0.47) MAPK8EGFRMAPK9IKBKBCSNK1D
SCHEMBL5875488 0.82 CSNK1D (0.46) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5457494 0.81 CSNK1D (0.51) MAPK8EGFRMAPK9CSNK1DMAPK14
SCHEMBL5890878 0.81 CSNK1D (0.51) MAPK8MAPK9IKBKBCSNK1DMAPK14
SCHEMBL5890227 0.81 CSNK1D (0.49) MAPK8MAPK9CSNK1DMAPK14MAPK13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US claimed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP claimed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 US claimed
US-7030134-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2006-04-18 US disclosed
US-6962914-B2 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2005-11-08 US disclosed
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds GUDMUNDSSON KRISTJAN (US) 2005-09-01 US disclosed
EP-1385847-B1 PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES SMITHKLINE BEECHAM CORP (US) 2005-06-01 EP disclosed
US-20040142941-A1 Therapeutic compounds SMITHKLINE BEECHAM CORPORATION 2004-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142941-A1 Therapeutic compounds PCSK9, ABCB1, ABCB11 MAPK8 4105/4885EGFR 1531/4885MAPK9 2943/4885
US-20050192303-A1 Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds DPYD, TYMP, P2RY4 MAPK8 1509/4885EGFR 2129/4885MAPK9 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.